Neuphoria Therapeutics (NEUP)
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nerv...
- Open
- 3.670
- High
- 3.700
- Low
- 3.650
- Prev. Close
- 3.680
- Volume
- 5.42K
- Turnover
- 19.89K
- Avg Price
- 3.670
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 1.36%
- 52wk High
- 21.400
- Volume Ratio
- 0.00
- Turnover Ratio
- 0.13%
Neuphoria Therapeutics Analyst Rating
View moreForecast & Rating
Jul 27, 2026Price forecast
$7.0091.78%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 day ago, 05:00 AM
Scancell secures up to US$25 million BlackRock loan facility
- benzinga_article · Sep 21 at 06:06 AM
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday
- TradingView · Sep 18 at 08:15 PM
Neuphoria Therapeutics Inc. FY 2026: Revenue $1.17M, Net loss $13.59M — 10-K Summary
- PUBT · Sep 18 at 08:11 PM
Neuphoria FY26 loss widens to $13.59 million; revenue drops 92.5% to $1.17 million
- TradingView · Aug 26 at 11:00 AM
NEUP Q4'26 Earnings: revenue estimate is 0 USD
- prnewswire · Aug 4 at 08:41 PM
16:40 ETAre CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
